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Abstract:  Staphylococcal enterotoxin B (SEB) and related exotoxins produced by 
Staphylococcus aureus are potent activators of the immune system and cause toxic shock 
in humans. Currently there is no effective treatment except for the use of intravenous 
immunoglobulins administered shortly after SEB exposure. Intranasal SEB induces   
long-lasting lung injury which requires prolonged drug treatment. We investigated the 
effects of rapamycin, an immunosuppressive drug used to prevent graft rejection, by 
intranasal administration in a lethal mouse model of SEB-induced shock. The results show 
that intranasal rapamycin alone delivered as late as 17 h after SEB protected 100% of mice 
from lethal shock. Additionally, rapamycin diminished the weight loss and temperature 
fluctuations elicited by SEB. Intranasal rapamycin attenuated lung MCP-1, IL-2, IL-6, and 
IFNγ by 70%, 30%, 64%, and 68% respectively. Furthermore, short courses (three doses) 
of rapamycin were sufficient to block SEB-induced shock. Intranasal rapamycin represents 
a novel use of an immunosuppressant targeting directly to site of toxin exposure, reducing 
dosages needed and allowing a wider therapeutic window.  
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1. Introduction 
Staphylococcal enterotoxin B (SEB) and structurally related exotoxins are bacterial virulence 
factors that cause a variety of diseases in humans, ranging from food poisoning, autoimmune diseases, 
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and toxic shock [1–7]. These toxins bind directly to the major histocompatibility complex (MHC) class II 
molecules on antigen-presenting cells and specific Vβ regions of the T-cell receptors [8–12]. 
Staphylococcal exotoxins (SE) are called superantigens due to their ability to polyclonally activate T cells 
at picomolar concentrations [7,10,13]. Their interactions with cells of the immune system result in a 
massive release of proinflammatory cytokines and chemokines [5,7,14]. These proinflammatory 
mediators enhance leukocyte migration, promote tissue injury, and coagulation [15]. In particular, 
tumor necrosis factor α (TNFα), interleukin 1 (IL-1) and IFNγ, are pathogenic at high concentrations  
in vivo and are responsible for fever and toxic shock induced by SE [16–20]. 
In humans, toxic shock syndrome is characterized by fever, hypotension, desquamation of skin, and 
dysfunction of multiple organ systems [1,4,6]. Humans are very sensitive to SEB intoxication and low 
doses cause lethal shock, especially via the respiratory route [21]. There is currently no effective 
therapeutic for treating SEB-induced shock except for the use of intravenous immunoglobulins which 
must be administered close to the time of toxin exposure [22]. Various murine models were used to 
develop therapeutics to mitigate SEB-induced shock, although mice are poor responders to SEB due to 
low affinity of these toxins to mouse MHC class II [9,11]. The most common murine models used rely 
on the use of sensitizing agents such as D-galactosamine, actinomycin D, lipopolysaccharide (LPS), or 
viruses to amplify the responses to SEB in toxic shock models [23–25]. Transgenic mice expressing 
human MHC class II were found to be a better animal model for examining the biological effects of 
superantigens, as they respond to toxins due to the higher affinity binding of SEs to human MHC class II 
molecules [26,27]. An alternative murine model of toxic shock using two low doses of SEB without 
the use of confounding sensitizing agents was developed recently [28]. In this “SEB-only” toxic shock 
model, SEB was administered intranasally and another dose of SEB was strategically given 2 h later by 
intraperitoneal (i.p.) or intranasal (i.n.) routes to induce systemic and pulmonary inflammation with 
lethality as an endpoint.  
We described in this study the effect of intranasal rapamycin, a FDA-approved immunosuppressant 
for kidney transplantation [29], in rescuing mice from SEB-induced shock. Rapamycin binds intracellularly 
to FK506-binding proteins, specifically FKBP12, the rapamycin-FKBP12 complex then binds to a 
distinct molecular target called mammalian target of rapamycin (mTOR) and this signaling pathway 
regulates metabolism as well as immune function [30]. Rapamycin suppresses T cell proliferation [30] 
and also upregulates the expansion of regulatory T cells [31]. Thus, rapamycin has effects on many types of 
effector T cells and is likely to be useful in mitigating SEB-activated immune responses.  
2. Results and Discussion 
2.1. Therapeutic Window of Rapamycin Treatment  
We previously established that rapamycin was effective in attenuating the biological effects of SEB 
in vitro and that multiple dosing schedule of intraperitoneal rapamycin protected mice from SEB-induced 
shock [32]. Due to the potency of rapamycin by the i.p. route, we investigated if lower doses of 
rapamycin administered only by the intranasal route would be protective against SEB-induced toxic 
shock. We explored the therapeutic window of treatment by administrating rapamycin at increasing 
intervals after SEB exposure. Intranasal administration of rapamycin (0.16 mg/kg) at 5 h after SEB Toxins 2012, 4  
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followed by the same dose i.n. at 24, 48, 72, 96 h (R5h5d) protected mice 100% (Table 1). Only 22% 
survival was recorded if intranasal rapamycin was delayed to 24 h after SEB (R245d). However, 
starting rapamycin at 5 h after SEB exposure but using one less dose was 100% effective (R5h4d). 
Importantly, low intranasal doses of rapamycin administered as late as 17 h after SEB exposure 
followed by doses at 23, 41 h was still 100% protective (R17h3d). The last dose at 41 h was necessary 
using this schedule of treatment, as eliminating this dose yielded only 70% survival. Kaplan Meier 
survival analysis (Figure 1) shows rapamycin extended survival times even in unprotected animals. 
Clinical signs of intoxication such as ruffled fur and lethargy observed with SEB-treated mice starting 
at 72 h were completely absent from the SEB plus rapamycin group.  
Table 1. Protective effects of intranasal rapamycin. 
Toxin + rapamycin (R) regiment 
a  Live/Total 
b 
SEB 0/9 
SEB + R at 5, 24, 48, 72, 96 h (R5h5d)  9/9 
SEB + R at 24, 30, 48, 72, 96 h (R24h5d)  2/9 
SEB 0/10 
SEB + R at 5, 24, 48, 72 h (R5h4d)  10/10 
SEB + R at 17, 23, 41 h (R17h3d)  10/10 
SEB + R at 17, 23 h (R17h2d)  7/10 
a Rapamycin (0.16 mg/kg) was administered i.n. at the specific time after SEB exposure as indicated. Bovine 
serum albumin controls (5 μg i.n. plus 2 µg i.p.) yielded no deaths (n = 10 animals per group). 
b Results 
obtained with rapamycin groups were statistically significant (except for the SEB + R24h5d group) from SEB 
groups (p < 0.02).  
Figure 1. Survival analysis of Staphylococcal enterotoxin B (SEB)-exposed mice treated 
with intranasal rapamycin. Number of animals and schedule of treatment are identical to 
those presented in Table 1. 
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2.2. Rapamycin Prevents Hyperthermia in SEB-Induced Shock Model  
Additional data were collected regarding temperature fluctuations in mice treated with SEB and 
those treated with SEB plus intranasal rapamycin given at various times after SEB (Figure 2). Mice 
given SEB experienced hypothermia starting at 48 h. This hypothermic response, indicating systemic 
shock that mimicked those found in other murine models [26,33,34], was completely absent in 
rapamycin-treated SEB-exposed mice. Reducing the duration of treatment with rapamycin to 72 h also 
protected mice from hyperthermia if treatment was started at 5 h (SEB + R5h4d). However, delaying 
treatment with rapamycin until 24 h resulted in shock like symptoms and hyperthermia (SEB + R24h5d). 
We progressively adjusted the time between the exposure of mice to SEB and rapamycin treatment to 
determine the maximum therapeutic window. A protective regimen of rapamycin starting at 17 h after 
SEB exposure followed by two other intranasal doses at 23 and 41 h also did not result in hypothermia. 
Clearly, rapamycin-treated and protected mice had minor temperature changes during the entire 
observation period. 
Figure 2. Intranasal rapamycin attenuated the hypothermic response of mice treated with 
SEB. Body temperatures of mice (n = 9 or n = 10) exposed to SEB and SEB plus 
rapamycin (0.16 mg/kg) at different time points after SEB exposure. Group identifiers are 
identical to those in Table 1. Points represent the means ± SD for each group. Grey arrow 
indicates time of SEB exposure and black arrows represent time of rapamycin 
administration for the SEB + R17h3d group. 
 
2.3. Rapamycin Prevents Weight Loss in SEB-Induced Shock Model 
Weight loss is another prominent indicator of SEB-induced shock in other animal models of 
superantigen-induced disease [16]. We therefore examined the effect of rapamycin on the weight of 
animals after intranasal SEB. SEB-exposed mice experienced weight loss of 3%–7% at 53 h with 
drastic weight reduction over time. Most of the rapamycin-treated, SEB-exposed mice had 1% change Toxins 2012, 4  
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in weight with some groups of mice gaining weight at later times (Figure 3). Mice receiving only two 
doses of rapamycin starting at 17 h (SEB + R17hd2) had 8% weight loss and weight remained at this 
level after 53 h (70% survival). Protection against temperature and weight fluctuations essentially 
paralleled the lethality data.  
Figure 3. Intranasal rapamycin prevented weight loss in mice treated with SEB. Weights 
of mice (n = 9 or n = 10) exposed to SEB and SEB plus rapamycin (0.16 mg/kg) at 
different time points after SEB exposure. Group identifiers are identical to those in Table 1. 
Points represent the average % weight change ± SD for each group. Grey arrow indicates 
time of SEB exposure and black arrows represent time of rapamycin administration for the 
SEB + R17h3d group. 
 
2.4. Rapamycin Attenuates Pulmonary Mediators 
Proinflammatory cytokines mediate the lethal and pathological effects of SEB and monocyte 
chemoattractant protein (MCP-1), interleukin 2 (IL-2), IL-6 and gamma interferon (IFNγ) are critical 
mediators in various mouse models of SEB-induced shock [19,23,26,28,32]. We next examined the 
effect of intranasal rapamycin on these pulmonary mediators. Figure 4 shows that high levels of MCP-1, 
IL-2, IL-6, and IFNγ were present in lung tissue at 42 h post-SEB treatment. In contrast, mice treated 
with rapamycin at 15 h followed by two additional doses at 21 and 39 h after SEB attenuated MCP-1, 
IL-2, IL-6, and IFNγ by 70%, 30%, 64%, and 68% respectively. These findings indicate a protective 
regimen of rapamycin is also effective in reducing the pulmonary mediators critical in initiating cell 
migration, cell activation, inflammation culminating in lung injury.  
Bacterial superantigens cause toxic shock and contribute to septic complications during infection 
and only antibodies to superantigens and steroids had proven to be effective when administered early 
after exposure. The present study demonstrates for the first time that intranasal low dose rapamycin 
was 100% effective in protecting mice from SEB-mediated shock. Previous studies of drug treatment 
for SEB- and other superantigen-induced shock models indicate a very narrow therapeutic window of Toxins 2012, 4  
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treatment [19,20]. This study indicates a much wider therapeutic window for rapamycin and that a new 
modality of using low doses of rapamycin even when administered 17 h after SEB was still protective 
100% against mortality. Concomitantly, intranasal rapamycin treatment reduced temperature and 
weight fluctuations in SEB-treated mice. 
Figure 4. Chemokine and cytokine assessment at 42 h in lungs of mice treated with 
intranasal rapamycin after SEB challenge. Values represent the mean ± SE for five mice 
and results are statistically significant (p < 0.05) between SEB and SEB + rapamycin group.  
 
Excessive release of cytokines contributes to the pathophysiological process of toxic shock as 
proinflammatory cytokines and chemokines regulate leukocyte migration and promote tissue injury. 
We previously reported that IL-2 and MCP-1 play a central role in this intranasal model of SEB-induced 
toxicity and lung inflammation [28]. IFNγ, the prototypic T helper 1 type cytokine produced by 
activated T cells is a key inflammatory cytokine as it synergizes with other cytokines to promote injury 
in addition to its anti-viral and anti-proliferative effects. IFNγ was also showed to affect metabolism as 
anti-IFNγ prevented weight loss in a D-galctosamine-sensitized murine model of SEB-induced shock [35]. 
Importantly, these critical cytokines were elevated in lung tissue after SEB exposure and were 
effectively reduced in lungs with rapamycin treatment. 
Based on the data presented, we propose that the mTOR signaling pathway plays an important role 
in the pathophysiology of SEB-mediated shock. The serine-threonine kinase, mTOR senses 
nutrient/growth factor inputs and cellular ATP levels via growth factor receptors and AMP-activated 
protein kinase, respectively [30]. In a separate pathway, IL-2 and IFNγ receptor signaling activates 
phosphoinositide 3-kinase (PI3K) which acts upstream of mTOR and provides a critical link between 
cytokine receptor signaling and energy homeostasis. mTOR complex 1 (mTORC1), one of two key 
proteins of mTOR signaling is sensitive to rapamycin. Rapamycin acts by binding to FKBP12, an 
immunophilin, blocking mTOC1 activity and inhibiting cell cycle progression and protein synthesis. In 
this regard, it is interesting that FKBP12 is also found in abundance in neuronal cells and blocking Toxins 2012, 4  
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FKBP12 was reported to reverse neuronal degeneration [36]. Bidirectional crosstalk between the 
neuroendocrine and the immune system is critical in the elimination of pathogens and proinflammatory 
cytokines are known to act on the hypothalamus to modulate neuronal pathways [37]. Future 
experiments should address if neuroimmunophilins are involved in the SEB-intoxication process.  
3. Experimental Section  
3.1. Materials 
Purified SEB was obtained from Toxin Technology (Sarasota, FL, USA). The endotoxin content of 
these preparations was <1 ng of endotoxin/mg protein, as determined by the Limulus amoebocyte 
lysate assay (BioWhittaker, Walkersville, MD, USA). Rapamycin and other reagents were from Sigma 
(St. Louis, MO, USA). 
3.2. Mouse Model of SEB-Induced Shock  
Male C3H/HeJ mice (National Cancer Institute, Frederick, MD, USA), weighing ~20 g each   
(7–10-weeks old), were housed in conventional microisolator cages. Sterile temperature/identification 
transponders (IPTT-300, Biomedic Data Systems, Seaford, DE, USA) were implanted subcutaneously 
into each animal 5–10 days before SEB and temperatures were monitored twice daily, between 8 and 
9 a.m. and again between 3 and 4 p.m. A previous study with a murine LPS-potentiated SEB-induced 
shock model using telemetry to monitor core temperature indicated a good correlation between core 
and subcutaneous temperature changes [34]. Initial weight of animals was recorded 3–7 days before 
SEB exposure and weight changes were recorded once daily between 3 and 4 p.m. Temperature and 
weight were recorded at the same time of the day to avoid diurnal effects. SEB was administered i.n. 
(50  μL), 5 µg/mouse with a micropipet and i.p. (200 µL), 2 µg/mouse with a tuberculin syringe   
(26G-3/8-inch needle) between 8 and 9 a.m., immediately after the first temperature measurements of 
the day. All i.n. doses were administered to mice previously anesthetized with an intramuscular   
(i.m.)-injected mixture of ketamine (2.4 mg/kg), acepromazine (0.024 mg/kg), and xylazine (0.27 mg/kg). 
There were 2 h of elapsed time between the first i.n. dose and the second i.p. dose of SEB as this was 
the optimal time previously determined to cause toxic shock without the use of synergistic agents [28]. 
Mice exposed to both doses of SEB were hypothermic starting between 48h–72 h and lethal endpoints 
were recorded up to 192 h after the first toxin dose. Controls consisted of C3H/HeJ mice given two 
doses of either bovine serum albumin (BSA, Sigma Chemical Corp.) or saline 2 h apart, similar to 
those of SEB-exposed mice (i.e., by i.n. and i.p.). For therapeutic investigations, mice (n = 9 or   
n = 10 mice per group as specified in figures) were given rapamycin i.n. at specific times after 
intranasal SEB exposure as described for each series of experiment. Intranasal rapamycin (0.16 mg/kg 
of body weight) in sterile saline was administered with a micropipette at the designated time points. 
Animals were monitored twice daily for illness and moribund condition for 96 h and as needed. 
Temperature and weight changes were measured daily up to 96–120 h. Temperature data were 
calculated as the mean temperature reading ± standard deviation of each group (n = 9 or n = 10 mice 
per group). Survival rates were recorded at 192 h.  Toxins 2012, 4  
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Research was conducted under an IACUC approved protocol in compliance with the Animal 
Welfare Act and other Federal statutes and regulations relating to animals and experiments involving 
animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, 
National Research Council, 1996. The facility where this research was conducted is fully accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care International. 
3.3. Cytokine and Chemokine Assays 
IL-2, IL-6, and MCP-1 were assayed by ELISA using matched pairs of specific anti-mouse 
antibodies as described previously [28,32]. Matched pairs of anti-mouse antibodies for cytokines and 
chemokines, and protein standards were purchased from BD Pharmingen (San Diego, CA, USA) and 
used in ELISA assays of cytokines according to manufacturer’s protocols. IFNγ was determined using 
Quantikine ELISA kit from R&D Systems (Minneapolis, MN, USA) as described in manufacturer’s 
instruction manual. 
Whole lungs (n = 5 mice per group) were excised from euthanized animals at 42 h post-SEB 
challenge, weighed, and frozen at −70 °C. Rapamycin treated mice received rapamycin (0.16 mg/kg) 
intranasally at 15 h after SEB followed by intranasal doses at 21 and 39 h. Immediately before 
cytokine assays, lungs were thawed and homogenized for 30 min at 4 °C in lysis buffer (Cell Signaling 
Technology, Danvers, MA, USA) to a 6.9 mg/mL concentration with Complete protease inhibitor 
(Roche Applied Science, Indianapolis, IN, USA). Homogenates were then centrifuged at 500× g for 
10  min, supernatants harvested, and the latter filtered through a 0.45 μM membrane (Millipore, 
Bedford, MA, USA). Bicinchoninic acid assay (Pierce, Rockford, IL, USA) was used to estimate 
protein concentrations in lung homogenates and results of lung homogenates were normalized based 
on protein concentration.  
3.4. Statistical Analysis  
Data were expressed as the mean ± SE and were analyzed for significant difference by Student’s t-test. 
Statistical comparisons of survival data were performed by Fisher’s exact test with Stata software 
(Stata Corp., College Station, TX, USA). Differences were considered significant if P was <0.05. 
4. Conclusions  
The novel application of intranasal rapamycin represents a new treatment modality for SEB 
introduced via the respiratory route. This concept of directing drug delivery to site of inflammation and 
injury has proven to be fast and effective as shown in the use of steroid for treating asthma. In applying 
this concept, we found low doses of intranasal rapamycin to be effective when administered as late as 
17 h after SEB. In comparison, our previous study with the steroid dexamethasone in the same   
SEB-induced shock model showed that dexamethasone was effective only if administered 5 h after 
SEB and was not protective when given at 17 h [32]. Furthermore, long courses of dexamethasone up 
to 96 h were required to prevent shock whereas a much shorter duration of treatment with intranasal 
rapamycin (41 h) was sufficient to prevent SEB-induced shock. The shorter duration of treatment and 
delayed start of treatment after SEB exposure with rapamycin is of obvious advantage as currently the Toxins 2012, 4  
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only effective treatment with anti-toxin/superantigen or steroid can prevent shock only if treatment is 
administered early post-SEB exposure.  
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